589 related articles for article (PubMed ID: 25440980)
21. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
22. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.
Mariné-Barjoan E; Saint-Paul MC; Pradier C; Chaillou S; Anty R; Michiels JF; Sattonnet C; Ouzan D; Dellamonica P; Tran A;
AIDS; 2004 Nov; 18(16):2163-70. PubMed ID: 15577649
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
[TBL] [Abstract][Full Text] [Related]
24. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
25. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
Pineda JA; Macías J
J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
[TBL] [Abstract][Full Text] [Related]
26. Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
Pineda JA; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Macías J
J Infect; 2012 Feb; 64(2):204-11. PubMed ID: 22138553
[TBL] [Abstract][Full Text] [Related]
27. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?
Verma S; Wang CH; Govindarajan S; Kanel G; Squires K; Bonacini M
Clin Infect Dis; 2006 Jan; 42(2):262-70. PubMed ID: 16355339
[TBL] [Abstract][Full Text] [Related]
28. HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.
Shuhart MC; Sullivan DG; Bekele K; Harrington RD; Kitahata MM; Mathisen TL; Thomassen LV; Emerson SS; Gretch DR
J Infect Dis; 2006 May; 193(9):1211-8. PubMed ID: 16586356
[TBL] [Abstract][Full Text] [Related]
29. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.
Macías J; Pineda JA; Lozano F; Corzo JE; Ramos A; León E; García-García JA; Fernández-Rivera J; Mira JA; Gómez-Mateos J
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):675-80. PubMed ID: 14574616
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
31. Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.
Li Vecchi V; Soresi M; Colomba C; Mazzola G; Colletti P; Mineo M; Di Carlo P; La Spada E; Vizzini G; Montalto G
World J Gastroenterol; 2010 Nov; 16(41):5225-32. PubMed ID: 21049556
[TBL] [Abstract][Full Text] [Related]
32. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
33. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection.
Li Vecchi V; Soresi M; Giannitrapani L; Di Carlo P; Mazzola G; Colletti P; Terranova A; Vizzini G; Montalto G
Int J Infect Dis; 2012 May; 16(5):e397-402. PubMed ID: 22425495
[TBL] [Abstract][Full Text] [Related]
35. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.
Moodie EE; Pant Pai N; Klein MB
PLoS One; 2009; 4(2):e4517. PubMed ID: 19223976
[TBL] [Abstract][Full Text] [Related]
36. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
[TBL] [Abstract][Full Text] [Related]
37. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Int J STD AIDS; 2005 Jan; 16(1):42-8. PubMed ID: 15705272
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
[TBL] [Abstract][Full Text] [Related]
39. Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus.
Endo T; Fujimoto K; Nishio M; Yamamoto S; Obara M; Sato N; Koike T
J Med Virol; 2009 Jun; 81(6):979-82. PubMed ID: 19382259
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
